Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
-
- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
-
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...